CTLA-4 mAb (9D9), InVivoPure
CTLA-4 mAb (9D9), InVivoPure - Image 2
CTLA-4 mAb (9D9), InVivoPure - Image 3

CTLA-4 mAb (9D9), InVivoPure

ID: AK3609P Category:

The CTLA-4 antibody (clone 9D9) is a monoclonal antibody that specifically targets the mouse CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4), also known as CD152.

This antibody is produced exclusively under serum-free conditions from hybridoma and purified with Protein-A or Protein-G affinity chromatography.

In stock

Delivery time: 2-5 days

From: 130,00 € Excl. VAT and delivery costs

Please contact us for larger quantities.

Endotoxin level ≤ 2 EU/mg

The CTLA-4 antibody (clone 9D9) is a monoclonal antibody that specifically targets the mouse
CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4), also known as CD152. CTLA-4 is a 33 kDa cell
surface receptor, belonging to the CD28 family of the immunoglobulin superfamily.
CTLA-4 plays a crucial role in immune regulation. 9D9 blocks the binding of murine CTLA-4-Ig to
B7-1-positive cells. It has an inhibitory effect and acts as an “off switch” for T cells. It binds to
the ligands CD80 and CD86 on antigen-presenting cells (APCs) and thereby inhibits the
activation of T cells. The CTLA-4 antibody clone 9D9 has been used to block CTLA-4 and
has been shown to enhance T-cell immunity against tumors.

This antibody is produced exclusively under serum-free conditions from hybridoma and
purified with Protein-A or Protein-G affinity chromatography.

 

Product-ID: AK3609P
Clone: 9D9
Immunogen: Not known
Host: Mouse
Clonality: Monoclonal
Isotype: Mouse IgG2b
Formulation: Clear Liquid, PBS, pH 7.4, 0.2 μm sterile filtered
Concentration: ≥ 1.00 mg/mL
Purity: ≥ 90 % (CGE, reducing conditions)
≤ 10 % aggregates (analytical SEC)
Endotoxin: ≤ 2 EU/mg (LAL test)
Storage: 2 - 8 °C
Recommended Isotype Control: Mouse IgG2b ĸ Isotype Control (AK3456P)

 

The product is for research use or for further manufacturing only and not for use in diagnostic or therapeutic procedures.

Additional information

Literature

[1] Simpson TR, Li F, Montalvo-Ortiz W, Sepulveda MA, Bergerhoff K, Arce F, Roddie C, Henry JY, Yagita H, Wolchok
JD, Peggs KS, Ravetch JV, Allison JP, Quezada SA. Fc-dependent depletion of tumor-infiltrating regulatory T cells
co-defines the efficacy of anti-CTLA-4 therapy against melanoma. J Exp Med. 2013 Aug 26;210(9):1695-710.
doi: 10.1084/jem.20130579. Epub 2013 Jul 29. PMID: 23897981; PMCID: PMC3754863.
[2] Selby MJ, Engelhardt JJ, Quigley M, Henning KA, Chen T, Srinivasan M, Korman AJ. Anti-CTLA-4 antibodies of
IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer
Immunol Res. 2013 Jul;1(1):32-42. doi: 10.1158/2326-6066.CIR-13-0013. Epub 2013 Apr 7. PMID: 24777248.
[3] Quezada SA, Peggs KS, Curran MA, Allison JP. CTLA4 blockade and GM-CSF combination immunotherapy alters
the intratumor balance of effector and regulatory T cells. J Clin Invest. 2006 Jul;116(7):1935-45. doi:
10.1172/JCI27745. Epub 2006 Jun 15. PMID: 16778987; PMCID: PMC1479425.
Document

Product Information Sheet – AK3609P
Notice

The product is for research use or for further manufacturing only and not for use in diagnostic or therapeutic procedures.

Reviews

There are no reviews yet.

Be the first to review “CTLA-4 mAb (9D9), InVivoPure”